[go: up one dir, main page]

MA27703A1 - Derives de diazepino-indole servant d'inhibiteurs de kinases - Google Patents

Derives de diazepino-indole servant d'inhibiteurs de kinases

Info

Publication number
MA27703A1
MA27703A1 MA28375A MA28375A MA27703A1 MA 27703 A1 MA27703 A1 MA 27703A1 MA 28375 A MA28375 A MA 28375A MA 28375 A MA28375 A MA 28375A MA 27703 A1 MA27703 A1 MA 27703A1
Authority
MA
Morocco
Prior art keywords
inhibitors
diazepino
kinases
indole derivatives
kinase inhibitors
Prior art date
Application number
MA28375A
Other languages
English (en)
Inventor
Sacha Ninkovic
Michael John Bennett
Eugene Yuanjin Rui
Fen Wang
Suzanne Pritchett Benedict
Min Teng
Yong Wang
Jinjiang Zhu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA27703A1 publication Critical patent/MA27703A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DEPOSANT Société dite : PFIZER INC. REVENDICATION DE PRIORITES US 9 Janvier 2003 60/439,396 Dérivés de diazépino-indole servant d'inhibiteurs de kinases Des composés tricycliques, inhibiteurs de protéine-kinases, telle que la CHK-1, répondant à la formule suivante (dans laquelle R2, R3 et R4 répondent aux définitions figurant dans le présent mémoire), des compositions pharmaceutiques contenant des quantités efficaces desdits composés ou leurs sels sont utiles, sous forme d'un agent unique ou en association avec un agent antinéoplasique ou un rayonnement thérapeutique ayant un effet antinéoplasique, pour le traitement de maladies ou d'affections, telles que des cancers.
MA28375A 2003-01-09 2005-07-08 Derives de diazepino-indole servant d'inhibiteurs de kinases MA27703A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09

Publications (1)

Publication Number Publication Date
MA27703A1 true MA27703A1 (fr) 2006-01-02

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28375A MA27703A1 (fr) 2003-01-09 2005-07-08 Derives de diazepino-indole servant d'inhibiteurs de kinases

Country Status (34)

Country Link
US (3) US6967198B2 (fr)
EP (2) EP1585749B1 (fr)
JP (1) JP3990718B2 (fr)
KR (1) KR100697746B1 (fr)
CN (1) CN1759118B (fr)
AP (1) AP2048A (fr)
AT (1) ATE404564T1 (fr)
AU (1) AU2004203977B2 (fr)
BR (1) BRPI0406701A (fr)
CA (1) CA2512683C (fr)
CR (1) CR7899A (fr)
CY (1) CY1108408T1 (fr)
DE (1) DE602004015724D1 (fr)
DK (1) DK1585749T3 (fr)
EA (1) EA009337B1 (fr)
EC (1) ECSP055911A (fr)
ES (1) ES2309484T3 (fr)
GE (1) GEP20084367B (fr)
HR (1) HRP20050624A2 (fr)
IL (1) IL169082A (fr)
IS (1) IS7884A (fr)
MA (1) MA27703A1 (fr)
MX (1) MXPA05007352A (fr)
NO (1) NO20053775L (fr)
NZ (1) NZ540638A (fr)
OA (1) OA13017A (fr)
PL (1) PL378372A1 (fr)
PT (1) PT1585749E (fr)
RS (1) RS20050522A (fr)
SI (1) SI1585749T1 (fr)
TN (1) TNSN05176A1 (fr)
UA (1) UA80733C2 (fr)
WO (1) WO2004063198A1 (fr)
ZA (1) ZA200504674B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831093B2 (en) * 2002-01-22 2004-12-14 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
BRPI0406701A (pt) * 2003-01-09 2005-12-20 Pfizer Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação
MX2007010073A (es) * 2005-02-18 2007-10-10 Astrazeneca Ab Metodo para determinar la respuesta de los inhibidores de chk1.
EP2330105A1 (fr) 2005-03-29 2011-06-08 ICOS Corporation Dérivés d'uree d'heteroaryle utilises pour inhiber CHK1
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
SI1896040T1 (sl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals, Inc. Fosforamidatna alkilatorska predzdravila
CN101384614A (zh) * 2005-08-15 2009-03-11 加利福尼亚大学董事会 Vegf活化的fas配体
WO2007023948A1 (fr) 2005-08-25 2007-03-01 Ube Industries, Ltd. PROCÉDÉ DE PRODUCTION D’ACIDE (S OU R)-α-AMINÉ OPTIQUEMENT ACTIF OU D’ESTER D’ACIDE (S OU R)-α-AMINÉ OPTIQUEMENT ACTIF
JP2009506077A (ja) * 2005-08-26 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非ステロイド性抗アンドロゲン剤
CA2648371A1 (fr) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polytherapie a base de (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
WO2007113647A1 (fr) * 2006-04-04 2007-10-11 Pfizer Products Inc. Formes polymorphes de (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-méthyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazépino[4,5,6-cd]indol-8-yl)acétamide
MX2009005300A (es) * 2006-11-17 2009-06-08 Schering Corp Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos.
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP2328890B1 (fr) * 2008-08-06 2012-01-25 Pfizer Inc. Composés 2-hétérocyclylamino pyrazines substituées en position 6 en tant qu'inhibiteurs de chk-1
WO2010040527A1 (fr) * 2008-10-10 2010-04-15 Priaxon Ag Nouveaux composés qui modulent l'activité kinase
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
EP2793882A4 (fr) * 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc Administration de promédicaments activés par l'hypoxie en combinaison à des inhibiteurs de chk1 pour le traitement du cancer
EP2797919B1 (fr) 2011-12-31 2017-03-29 BeiGene, Ltd. Pyridophthalazinones tétra ou pentacycliques fusionnés à utiliser en tant qu'inhibiteurs de parp
HUE035153T2 (en) * 2011-12-31 2018-05-02 Beigene Ltd Condensed tetra- or pentacyclic dihydrodiazepinocarbazolone derivatives as PARP inhibitors
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
WO2015013579A1 (fr) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions permettant d'améliorer l'avantage thérapeutique du bisantrène
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
HRP20191375T1 (hr) 2014-06-17 2019-11-01 Vertex Pharma Postupak liječenja raka upotrebom kombinacije chk1 i atr inhibitora
NZ739876A (en) * 2015-08-25 2022-09-30 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
TWI806840B (zh) 2016-09-27 2023-07-01 英屬開曼群島商百濟神州有限公司 使用包含parp抑制劑的組合產品治療癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN115433187B (zh) 2017-02-28 2023-10-27 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
CN111108105B (zh) * 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
EP3461480A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
CN113631179A (zh) * 2019-01-25 2021-11-09 努梅迪公司 用于治疗特发性肺纤维化的方法
WO2021018298A1 (fr) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 Composés acyloxime à sept chaînons indolo servant d'inhibiteurs de parp
JP7260718B2 (ja) 2019-11-29 2023-04-18 メッドシャイン ディスカバリー インコーポレイテッド ジアザインドール誘導体及びそのＣｈｋ１阻害剤としての使用
WO2022011458A1 (fr) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Conjugués inhibiteurs de nicotinamide phosphoribosyltransférase (nampt) et leurs utilisations
TW202214649A (zh) * 2020-07-31 2022-04-16 大陸商正大天晴藥業集團股份有限公司 用作ｐａｒｐ抑制劑的吲哚并七員醯肟類似物的結晶及其製備方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
EP1135135A4 (fr) 1998-09-18 2006-08-09 Smithkline Beecham Corp Inhibiteurs de la kinase chk1
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
PT1144609E (pt) 1999-08-27 2008-05-28 Novartis Vaccines & Diagnostic Oligonucleótidos anti-sentido quiméricos e suas formulações para transfecção de células
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
ES2239037T3 (es) 1999-09-22 2005-09-16 Canbas Co., Ltd. Metodos y composiciones para inhibir la deteccion del ciclo celular en g2 y sensibilizar celulas a agentes dañinos del dna.
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6887996B2 (en) 2000-12-01 2005-05-03 Guilford Pharmaceuticals Inc. Compounds and their use
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
BRPI0406701A (pt) * 2003-01-09 2005-12-20 Pfizer Compostos tricìclicos inibidores da proteìna cinase para melhorar a eficácia de agentes antineoplásicos e da terapia de radiação

Also Published As

Publication number Publication date
US20060004052A1 (en) 2006-01-05
IS7884A (is) 2005-06-09
JP3990718B2 (ja) 2007-10-17
US7462713B2 (en) 2008-12-09
CY1108408T1 (el) 2014-02-12
KR20050092397A (ko) 2005-09-21
PT1585749E (pt) 2008-10-23
RS20050522A (sr) 2007-12-31
TNSN05176A1 (fr) 2007-06-11
CN1759118A (zh) 2006-04-12
EP1947102A1 (fr) 2008-07-23
PL378372A1 (pl) 2006-04-03
IL169082A (en) 2011-02-28
ATE404564T1 (de) 2008-08-15
CA2512683A1 (fr) 2004-07-29
ECSP055911A (es) 2005-11-22
EP1585749A1 (fr) 2005-10-19
UA80733C2 (en) 2007-10-25
DK1585749T3 (da) 2008-09-22
NO20053775D0 (no) 2005-08-08
NZ540638A (en) 2007-12-21
BRPI0406701A (pt) 2005-12-20
HRP20050624A2 (en) 2006-02-28
WO2004063198A1 (fr) 2004-07-29
EA200500893A1 (ru) 2006-02-24
CN1759118B (zh) 2010-12-08
US20070135415A1 (en) 2007-06-14
OA13017A (en) 2006-11-10
SI1585749T1 (sl) 2008-10-31
KR100697746B1 (ko) 2007-03-22
HK1086257A1 (en) 2006-09-15
DE602004015724D1 (de) 2008-09-25
GEP20084367B (en) 2008-05-13
AP2048A (en) 2009-09-24
ZA200504674B (en) 2006-07-26
US20050075499A1 (en) 2005-04-07
US6967198B2 (en) 2005-11-22
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (fr) 2008-08-13
CR7899A (es) 2005-08-05
NO20053775L (no) 2005-09-16
CA2512683C (fr) 2010-03-16
EA009337B1 (ru) 2007-12-28
ES2309484T3 (es) 2008-12-16
JP2006516274A (ja) 2006-06-29
AP2005003353A0 (en) 2005-09-30
AU2004203977B2 (en) 2010-06-17
US7132533B2 (en) 2006-11-07
MXPA05007352A (es) 2006-02-17

Similar Documents

Publication Publication Date Title
MA27703A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
AU2014372166B2 (en) Pharmaceutical combinations
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
MA54608B1 (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA27568A1 (fr) Derives de pyrrolopyrimidine
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
BR0113448A (pt) Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase
JP2005527510A (ja) 癌の治療において一酸化窒素模倣体を使用するための製剤および方法
US20020156023A1 (en) Lometrexol combination therapy
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
MXPA06000191A (es) Combinacion de los inhibidores de src cinasa y agentes quimioterapeuticos para el tratamiento de enfermedades proliferativas.
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
EP1868435A2 (fr) Combinaisons, procedes et compositions de traitement du cancer
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
MA27716A1 (fr) 4-aminopyrimidine-5-one
KR100392573B1 (ko) 암 치료용 ＨＭＧ ＣｏＡ 환원효소와 조합한 화합물
Willis et al. Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma
ZA200704914B (en) Use of Thiazolidinone derivatives as antiangiogenic agents
Santos et al. New drugs for chronic myelogenous leukemia
MA27963A1 (fr) Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US10196378B2 (en) Inhibitors of BCR-ABL mutants and use thereof